|Earnings Power Value||0|
|Net Current Asset Value||0|
|Median P/S Value||0|
|Peter Lynch Value||0|
|DCF (FCF Based)||0|
|DCF (Earnings Based)||0|
Prem Watsa (Trades, Portfolio) and Warren Buffett (Trades, Portfolio) have many things in common. Watsa runs global insurance conglomerate Fairfax Financial Holdings (TSX:FFH), and Buffett oversees the famed insurance holding company Berkshire Hathaway (BRK.A)(BRK.B). Both financiers also invest their companies' “float,” or money an insurer has collected but not paid out in premiums yet.
They can boast unmatched track records with their respective businesses, too. Buffett has compounded book value at Berkshire Hathaway by 19.1% annually since 1965. Watsa compounded book value at Fairfax Financial by 19.5% since 1985.
Further overlap occurs in their
During May and June, GuruFocus Forum users discussed mergers and acquisitions in light of the landmark federal court ruling that enabled AT&T Inc. (T) to complete its merger with Time Warner Inc. (TWX).
Telecom company completes merger with Time Warner days after federal approval
AT&T closed its merger with Time Warner two days after U.S. District Court Judge Richard Leon approved the transaction. The Dallas-based telecom company issued 1.437 shares of its common stock and paid $53.75 in cash per Time Warner share, for a total transaction of 1.185 billion AT&T common
Bayer AG (XTER:BAYN)(BAYRY) announced on Thursday that it closed its merger with Monsanto Co. (MON), a company Warren Buffett (Trades, Portfolio) invested in 7.26 million shares during the first quarter.
The German health care and chemical conglomerate acquired the St. Louis-based agriculture company for $66 billion, or $128 per share. JPMorgan Chase & Co. (JPM) assisted Bayer with the transaction for “the largest acquisition in [Bayer’s] history,” according to the press release.
CEOs comment on landmark merger closing
Hugh Grant, outgoing chairman and CEO of Monsanto, said the closing represents a key milestone toward the company’s
The stock in Monsanto Co. (MON) closed slightly at $127.83 a share, up 0.24%, following Bayer AG’s (OTCPK:BAYRY) announcement about its plans to complete the $63 billion merger before Friday.
The German global pharmaceutical and life sciences company counts on receiving all the remaining approvals from regulators by tomorrow.
Werner Baumann is the chairman of Bayer's board of management. He commented: “The acquisition of Monsanto is a strategic milestone in strengthening our portfolio of leading businesses in health and nutrition. We will double the size of our agriculture business and create a leading innovation engine in agriculture, positioning
The U.S. Department of Justice has approved the union between Monsanto Co. (MON) and Bayer (BAYA).
U.S. regulators had feared that consumers and farmers would be harmed by the merger. But the two companies have allayed those concerns, Bloomberg reports. The U.S. antitrust division has imposed conditions regarding asset sales in order to keep open competive channels. In fact, the agreement between Bayer and Monsanto with the U.S. authorities involves the largest sale of assets ever requested in a merger case.
The $62.5 billion deal is just one step from its final conclusion. The companies
Monsanto Company (MON) has been steadily rising since the announcement that its $62.5 billlion merger with Bayer (BAYA) will close soon.
Bayer CEO Werner Baumann said the deal will be completed by mid-June. Monsanto is expected to give a significant contribution to Bayer’s core net profit starting in 2019 and to its adjusted earnings before interest taxes depreciation and amortization’s (EBITDA).
On Monday, Monsanto was trading at over $127 per share, up 0.51%, reaching its 52-week high.
At the annual meeting of Bayer shareholders, Baumann said that “the company expects synergies to deliver annual contributions of
Shares of Monsanto (MON) were unexpectedly flat on Tuesday following the news that the U.S. global agrochemical and agricultural biotechnology corporation received clearance from the antitrust of India as part of a merger with Bayer AG.
Now, the $62.5 billion worth merger between Monsanto and Bayer is just a whisper way from its conclusion.
Monsanto is trading at $125.7 per share and the stock is up 7% so far this year.
The stock is trading above the 200, 100 and 50-SMA lines, as illustrated by the chart powered by GuruFocus and it is only $1.07
The stake of Monsanto Co. (MON) was trimmed by 10.53%, impacting the portfolio by -0.87%.
The company with its subsidiary provides agricultural products for farmers. It has a market cap of $55.18 billion and an enterprise value of $60.63 billion.
GuruFocus gives the company a profitability and growth rating of 8 out of 10. Its return on equity (ROE) of 37.90% and return on assets (ROA) of 11.29% are underperforming 85% of companies in the Global Agricultural
NEW YORK, May 07, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Forestar Group Inc (:FOR), Altria Group, Inc. (:MO), Investors Bancorp, Inc. (ISBC), Brighthouse Financial, Inc. (BHF), Monsanto Company (:MON), and Cleveland-Cliffs Inc. (:CLF), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
After months of back-and-forth negotiations between Bayer AG (XTER:BAYN) (BAYRY) and regulators, the Wall Street Journal reported on Monday the company made a deal with the U.S. Justice Department for antitrust approval of its $62.5 billion takeover of Monsanto Co. (MON).
The German drugs and pesticides company agreed to sell additional assets in exchange for approval, which has been a long time coming. Bayer first approached the world’s largest seeds company with a buyout offer in 2016, increasing the price multiple times before Monsanto finally accepted. According to CNBC, the combined company will control more than a
Shares of Monsanto Co. (MON) are expected to soar on the heels of the news the European Union has approved Bayer AG's (XTER:BAYN) $62.5 billion takeover.
The European Union's antitrust approval was conditional to the positive valuation of Bayer’s deal with BASF Group to sell certain seed and pesticide assets in consideration of about $7.2 billion and to give BASF a license to use its digital agriculture technology.
Bayer has also agreed to sell its vegetable seeds business to BASF.
Brazil and China have already given the merger deal a greenlight, but it is currently under the scrutiny
The firm invested in 163,000 shares of Aetna Inc. (AET), expanding the portfolio by 2.25%.
The diversified health care benefits company has a market cap of $57.56 billion and an enterprise value of $60.62 billion.
GuruFocus gives the company a profitability and growth rating of 7 out of 10. Its return on equity of 12.10% and return on assets of 3.23% are underperforming 69% of companies in the Global Health Care Plans industry. Its financial strength
Monsanto Co. (MON) closed at $122.70 per share on Wednesday. The stock dipped 0.16% compared to the previous day’s closing. By early Thursday, however, shares were up 0.86% to just under $124 a share.
More upsides are highly expected in the share price of the U.S. global agrochemical and agricultural biotechnology corporation over the next days of trading on the heels of Werner Baumann’s – Chief Executive Officer of Bayer AG - statement on the Monsanto – Bayer merger.
About the merger with Monsanto, at the presentation of Bayer’s financial results for full fiscal 2017, Werner Baumann said:
One of the baby Berkshires is sinking its teeth into the Food Network and the Cooking Channel.
The New York-based Leucadia effectively seized on a huge opportunity, which emerged as a result of a $15 billion deal between the Food Network’s parent, Scripps Networks Interactive Inc. (SNI), and Discovery Communications (DISCA). The two companies just recently made their union official.
Tennessee-based Scripps Networks Interactive was among the major positions established by the company in the fourth quarter.
[url=http://www.gurufocus.com/StockBuy.php?GuruName=Warren+Buffett]Warren Buffett[/url] ([url=http://www.gurufocus.com/StockBuy.php?GuruName=Warren+Buffett]Trades[/url], [url=http://www.gurufocus.com/holdings.php?GuruName=Warren+Buffett]Portfolio[/url])’s portfolio reveal Thursday showed that investment managers at his company bought shares of Teva Pharmaceuticals Industries (TEVA), Monsanto Co. (MON) and Apple (AAPL) in the fourth quarter. The new filing also showed that Buffett nearly ended his stake in IBM Corp. (IBM).
Teva Pharmaceutical Industries Ltd.
Berkshire Hathaway acquired 18,875,721 shares of a new stake in Teva Pharmaceuticals, which had a fourth-quarter average price of $15 per share. The holding represented 0.19% of the portfolio.
Teva Pharmaceutical Industries Ltd. has a market cap of $19.87 billion; its shares were traded around $19.33 Wednesday
Monsanto (MON) is updating shareholders with a quarterly dividend payment for the three months of fiscal 2018 that wrap up on Feb 28.
The U.S. global agrochemical and agricultural biotechnology corporation will pay its shareholders a quarterly dividend of 54 cents per ordinary share. As authorized by its board of directors, this quarterly dividend is on par with the previous one.
The dividend will be paid by Monsanto on April 27 to its shareholders of record as of April 6. The ex-dividend date is scheduled for April 5. Monsanto is a faithful payer of dividends. If the quarterly distribution is
Monsanto Co. (MON) closed up 0.4% on the New York Stock Exchange on Thursday after posting first quarter 2018 results.
Higher glyphosate pricing triggered robust growth in earnings. However, what likely made the stock rally was the company's update on the merger with Bayer.
The U.S. multinational agribusiness corporation said that the merger is progressing as planned and is expected to close in the first part of 2018. From this merger, Monsanto expects to accelerate the growth of products it offers to farmers, the company said.
The synergy coming from the merger is
As reported by FOX Business yesterday, Dec. 13, Scott Partridge – Monsanto’s (MON) vice president of global strategy – criticised in an interview Minnesota's announced restrictions on how the herbicide dicamba can be used by the farmers in 2018:
"There's no scientific reason to have a cutoff date or a temperature limit. There is no testing that supports it," he said.
In order to reduce herbicide drift to neighboring fields, the state of Minnesota has scheduled for June 20 the last date on which it is possible to apply for the herbicide.
Dec. 4, Monsanto (MON) provided the shareholders with two important dates:
The first one is about the shareholders’ meeting, which will take place in Chesterfield, Missouri, where Monsanto’s global R&D department is headquartered, on Jan. 31. The record date for the annual meeting is scheduled for Dec. 15.
The second date concerns the payment of the quarterly dividend for the first three months of fiscal 2018, which ended Nov. 30.
The U.S. global agrochemical and agricultural biotechnology corporation will pay its shareholders a quarterly dividend of 54 cents per ordinary share.
The dividend will be paid by Monsanto on Jan.
Risk arbitrage is a favorite of top money managers as you'll see by the guru ownership in each of these below. To do it like the Warren Buffetts (Trades, Portfolio) of the world, you need to be comfortable leveraging longer-term cash positions to buy and sell stocks for short-term gains with borrowed money. For example, if you’ve built a $2.84 million portfolio on 10 shares of Berkshire Hathaway (BRK.A)(BRK.B), you would keep that position intact and buy short-term “workout” positions on margin, understanding that if the position went the wrong direction, you may have to liquidate one